Mass High Tech
SIGNABLOK INC
Is this your company?
Update it or Add a Logo
Logos place your company at the
top of the search results!
About:
SignaBlok is using groundbreaking drug discovery science and cutting edge nanotechnologies to develop novel targeted therapeutics and diagnostics for cancer, atherosclerosis, inflammatory and autoimmune diseases.
Headlines from Mass High Tech about SIGNABLOK INC
Print this Listing
Product Information
| Industry Classification | Biopharma/Biotechnology |
| Primary Business Focus | Biotechnology - Pharmaceutical |
| Other Business Offering | Biotechnology - Non-Pharmaceutical, Nanotechnology, Other Medical |
Details
| Year Established | 2009 |
| Ownership Type | Private |
| Venture Funding | Subscriber access only |
| No. of Employees at this location | Subscriber access only |
| Total Number Employees | Subscriber access only |
| Anticipated Workforce Changes | Subscriber access only |
| Annual Sales | Subscriber access only |
Contacts
| Alexander Sigalov | President/Founder | email available to subscribers |
* Downloads will not contain Personnel E-mail addresses
Search the Directory
Company Overview
| Focus | Biotechnology - Pharmaceutical |
| Location | Shrewsbury, MA |
| Size | Subscriber access only |
| Website | http://www.signablok.com |
| Revenue | Subscriber access only |
Contact Information
| Address |
PO Box 4064 Shrewsbury, MA, 01545 |
| Phone | 203-505-3807 |
| Subscriber access only | |
| Website | www.signablok.com |
New England Tech Directory
| Browse
| Subscribe
| Advertise
| Networking
| About Us
| Search
| 
RSS Feeds
| 
| Directory License
| Update User Info
| Directory Privacy Policy
| Logout
© 2012 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of bizjournals.
Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com
Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.